Table 2 Tumor nuclear CSE1L expression and clinical parameters in CRC
| Â | Nuclear CSE1L | Total | P | |
|---|---|---|---|---|
| Â | Low (1+) | High (2+ or 3+) | Â | Â |
Sex | Â | Â | Â | Â |
female | 33 (63.5) # | 19 (36.5) | 52 | 0.099 |
male | 37 (48.7) | 39 (51.3) | 76 | Â |
Grade | Â | Â | Â | Â |
well | 3 (75) | 1 (25) | 4 | 0.699 |
moderate | 63 (53.8) | 54 (46.2) | 117 | Â |
poor | 4 (57.1) | 3 (42.9) | 7 | Â |
T status | Â | Â | Â | Â |
T1+T2 | 13 (61.9) | 8 (38.1) | 21 | 0.467 |
T3+T4 | 57 (53.3) | 50 (46.7) | 107 | Â |
Lymph node metastasis | Â | Â | Â | Â |
no | 40 (53.3) | 35 (46.7) | 75 | 0.714 |
yes | 30 (56.6) | 23 (43.4) | 53 | Â |
Distance metastasis | Â | Â | Â | Â |
no | 62 (55.9) | 49 (44.1) | 111 | 0.497 |
yes | 8 (47.1) | 9 (52.9) | 17 | Â |
Stage | Â | Â | Â | Â |
I | 12 (60) | 8 (40) | 20 | 0.346 |
II | 23 (47.9) | 25 (52.1) | 48 | Â |
III | 28 (63.6) | 16 (36.4) | 44 | Â |
IV | 7 (43.8) | 9 (56.2) | 16 | Â |
Stage | Â | Â | Â | Â |
I/ II | 35 (51.5) | 33 (48.5) | 68 | 0.436 |
III/IV | 35 (58.3) | 25 (41.7) | 60 | Â |
Overall survival | Â | Â | Â | Â |
≤5 y | 39 (52.7) | 35 (47.3) | 74 | 0.579 |
≥5 y | 31 (57.4) | 23 (42.6) | 54 |  |